Psychiatric applications of bromocriptine therapy
by
Sitland-Marken PA, Wells BG,
Froemming JH, Chu CC, Brown CS
Division of Pharmacy Practice,
School of Pharmacy,
University of Missouri,
Kansas City 64108-2792.
J Clin Psychiatry 1990 Feb; 51(2):68-82


ABSTRACT

Bromocriptine, an ergot alkaloid derivative that possesses both dopamine agonist and antagonist activity, has been studied in a broad spectrum of psychiatric illnesses. The literature consists primarily of case reports and small trials limited by methodological shortcomings. The authors critically review these reports, focusing on efficacy, mechanistic issues, dosing, side effects, predictors of response, monitoring parameters, and practical guidelines. Preliminary data suggest bromocriptine may have promise in the treatment of neuroleptic malignant syndrome, cocaine withdrawal, and depression. At present, the agent appears less efficacious in the treatment of tardive dyskinesia, mania, and schizophrenia; however, doses in these trials may have been excessive, producing primarily postsynaptic agonist effects. More extensive clinical trials are required to clearly define the role of bromocriptine in psychiatry.
Mania
Reward
Cocaine
Piribedil
Pergolide
Roxindole
Selegiline
Amineptine
Pramipexole
Nomifensine
Bromocriptine
Methylphenidate
Bromocriptine and cats
The nucleus accumbens
Bromocriptine v lisuride
Dopaminergics and depression
Rats, bromocriptine and cocaine
Bromocriptine versus imipramine
Bromocriptine for nicotine addicts
Bromocriptine (Parlodel) v cabergoline (Dostinex)


Refs
and further reading

HOME
HedWeb
Nootropics
erythroxylum-coca.com
Future Opioids
BLTC Research
MDMA/Ecstasy
Superhapiness?
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Good Drug Guide

The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family